Last reviewed · How we verify
NCT04105634
Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT
EARLY_PHASE1 trial testing FNOS in Cardiac Amyloidosis in 3 participants. Terminated before completion.
14 October 2024
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 3 |
| Start date | 1 October 2019 |
| Primary completion | 14 October 2024 |
| Estimated completion | 14 October 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- FNOS — full drug profile →
- Florbetaben (FLORBETABEN) — full drug profile →
Conditions studied
- Cardiac Amyloidosis — all drugs for Cardiac Amyloidosis →
Sponsor
University of Pennsylvania
Who can join
18 and older, any sex, with Cardiac Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The research study is being conducted to test how two different types of Positron Emission Tomography (PET/CT) scans could be used to image a type of heart disorder called amyloidosis (AL). There will be two groups in the study. One group will have PET/CT scans using an imaging drug called 18F-NOS and the other group will have PET/CT scans using a drug called Florbetaben. subject will be assigned to one of the groups when she/he agrees to be in the study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Novel Tracers and Radionuclides in PET Imaging.
Mason C, Gimblet GR, Lapi SE, Lewis JS. · · 2021 · cited 10× · PMID 34392925 · DOI 10.1016/j.rcl.2021.05.012
Verify or expand the search:
- PubMed search for NCT04105634
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiac Amyloidosis
Currently open trials in the same condition.
- NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
- NCT06788535 — Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis · Phase 3 · active not recruiting
- NCT06458374 — ATTR Cardiac Amyloidosis in a Selected Population · recruiting
- NCT06427304 — Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure · recruiting
- NCT06907836 — Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine · recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04105634 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 12 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04105634.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing